A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer
Jamunarani Veeraraghavan(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Matthew P. Goetz(Mayo Clinic), Jae C. Chang, Carolina Gutiérrez(Baylor College of Medicine), Antonio C. Wolff(Johns Hopkins University), Carmine De Angelis(Baylor College of Medicine), Sabrina Herrera(Mayo Clinic), Alejandro Contreras(Baylor College of Medicine), C. Kent Osborne(Baylor College of Medicine), Ian E. Krop(Yale Cancer Center), Britta Weigelt(Memorial Sloan Kettering Cancer Center), Andres Forero(University of Alabama at Birmingham), Suzanne A.W. Fuqua(Baylor College of Medicine), Ingrid A. Mayer(Vanderbilt University), Mothaffar F. Rimawi(Baylor College of Medicine), Susan G. Hilsenbeck(Baylor College of Medicine), Jorge S. Reis‐Filho(Institute of Cancer Research), Paolo Nucíforo(Vall d'Hebron Institute of Oncology), Anne C. Pavlick(Baylor College of Medicine), Rena Mao(Breast Center), Rita Nanda(University of Chicago), Aleix Prat(Breast Cancer Research Foundation), T. Wang(Breast Center)
Cited by 42
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k